Porter JK - Search Results

1

Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes.

Hatswell AJ, Porter JK. Hatswell AJ, et al. Among authors: porter jk. Appl Health Econ Health Policy. 2019 Jun;17(3):391-397. doi: 10.1007/s40258-018-0444-0. Appl Health Econ Health Policy. 2019. PMID: 30520000

2

Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective.

Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S, Villa G, Shah N, Tepper S, Dodick D. Lipton RB, et al. Among authors: porter jk. J Med Econ. 2018 Jul;21(7):666-675. doi: 10.1080/13696998.2018.1457533. Epub 2018 Apr 3. J Med Econ. 2018. PMID: 29571276 Free article.

3

The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight.

Hatswell AJ, Porter J, Lee D, Hertel N, Latimer NR. Hatswell AJ, et al. Value Health. 2016 Dec;19(8):1055-1058. doi: 10.1016/j.jval.2016.04.013. Epub 2016 Jun 9. Value Health. 2016. PMID: 27987632 Free article.

4

Migraine day frequency in migraine prevention: longitudinal modelling approaches.

Di Tanna GL, Porter JK, Lipton RB, Brennan A, Palmer S, Hatswell AJ, Sapra S, Villa G. Di Tanna GL, et al. Among authors: porter jk. BMC Med Res Methodol. 2019 Jan 23;19(1):20. doi: 10.1186/s12874-019-0664-5. BMC Med Res Methodol. 2019. PMID: 30674285 Free PMC article.

5

Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials.

Di Tanna GL, Porter JK, Lipton RB, Hatswell AJ, Sapra S, Villa G. Di Tanna GL, et al. Among authors: porter jk. Health Qual Life Outcomes. 2019 Nov 12;17(1):171. doi: 10.1186/s12955-019-1242-6. Health Qual Life Outcomes. 2019. PMID: 31718662 Free PMC article.

6

A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe.

Lee DC, Gladwell D, Hatswell AJ, Porter J, Brereton N, Tate E, Saunders AL. Lee DC, et al. Health Econ Rev. 2014 Apr 12;4:6. doi: 10.1186/s13561-014-0006-6. eCollection 2014. Health Econ Rev. 2014. PMID: 24949280 Free PMC article.

7

Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.

Lee D, Porter J, Hertel N, Hatswell AJ, Briggs A. Lee D, et al. BioDrugs. 2016 Aug;30(4):307-19. doi: 10.1007/s40259-016-0178-1. BioDrugs. 2016. PMID: 27177756

8

The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Models Due to Differing Patient Weights.

Hatswell AJ, Porter J, Hertel N, Lee D. Hatswell AJ, et al. Value Health. 2014 Nov;17(7):A323-4. doi: 10.1016/j.jval.2014.08.568. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200530 Free article. No abstract available.

9

Cost-Effectiveness Analysis of Ipilimumab in Previously Untreated Patients With Unresectable Malignant Melanoma in Scotland.

Lee D, Porter J, Hatswell AJ, Hertel N, Walker A. Lee D, et al. Value Health. 2014 Nov;17(7):A549-50. doi: 10.1016/j.jval.2014.08.1789. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201787 Free article. No abstract available.

10

Modelling Survival in the Presence of Different Mechanisms of Action: Ipilimumab and Vemurafenib in Advanced Melanoma.

Lee D, Porter J, Hertel N, Hatswell AJ. Lee D, et al. Value Health. 2014 Nov;17(7):A557. doi: 10.1016/j.jval.2014.08.1832. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201833 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters